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Background: Primary high-risk human papillomavirus (hrHPV) testing in cervical cancer screening shows relatively low specificity,
which makes triage testing necessary. In this study, DNA methylation analysis was compared with cytology for triage testing in
hrHPV-positive women. Moreover, feasibility of DNA methylation analysis directly on brush-based self-sampled specimens was
assessed.
Methods: Non-responding women from population-based screening were invited to self-collect a cervico-vaginal specimen for
hrHPV testing; hrHPV-positive women were referred to a physician for triage liquid-based cytology. DNA methylation analysis was
performed on 128 hrHPV-positive physician-collected triage samples and 50 matched brush self-samples with QMSP for
C13ORF18, EPB41L3, JAM3 and TERT.
Results: In physician-taken triage material, DNA methylation analysis of JAM3 showed the highest combined specificity (88%) and
sensitivity (82%) for detection of CIN3þ , whereas cytology showed a specificity of 48% and a sensitivity of 91%. Out of 39 women
with abnormal cytology and normal histology (false-positive by cytology), 87% were negative for JAM3 and 90% for C13ORF18
methylation. Agreement between DNA methylation analysis performed directly on the matched self-sampled material and
physician-taken samples was 88% for JAM3 (k¼ 0.75, Po0.001) and 90% for C13ORF18 (k¼ 0.77; Po0.001).
Conclusions: DNA methylation analysis as a triage test in hrHPV-positive women is an attractive alternative to cytology.
Furthermore, DNA methylation is feasible directly on brush-based self-samplers and showed good correlation with matched
physician-taken samples. Direct molecular triage on self-collected specimens could optimise the screening program, especially for
non-responders, as this would eliminate the need for an additional physician-taken scraping for triage testing.
Cytomorphological assessment of cervical scrapings is still the
most common method used in population-based cervical cancer
screening. Several randomised trials have demonstrated that
high-risk human papillomavirus (hrHPV) testing shows higher
sensitivity for detecting (pre)malignant cervical lesions and
consequently improves screening for cervical cancer (Mayrand
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et al, 2007; Arbyn et al, 2012; Rijkaart et al, 2012a; Ronco et al,
2013). However, hrHPV testing has a lower specificity compared
with cytology, especially in younger women (Cuzick et al, 2006).
To prevent unnecessary referrals to the gynaecologist, a triage test
for hrHPV-positive women is necessary. Currently, cytological
triage is the approach that is mostly advocated (Rijkaart et al,
2012b; Zorzi et al, 2013; Dijkstra et al, 2014). DNA methylation
analysis of cancer-specific genes with quantitative methylation-
specific PCR (QMSP) might be an alternative triage tool for early
detection of cervical neoplasia (Lai et al, 2008; Overmeer et al,
2009; Yang et al, 2010). DNA promoter methylation of tumour
suppressor genes is an early event in cervical carcinogenesis
(Woodman et al, 2007; Yang et al, 2010). Several studies indeed
reported that DNA methylation analysis could be a valuable
objective triage tool for hrHPV-positive women (Hesselink et al,
2011; Overmeer et al, 2011; Eijsink et al, 2012). Scenario analysis
comparing triage testing either by cytological examination or DNA
methylation analysis after primary HPV screening showed that
DNA methylation analysis as triage test will detect more CIN3
lesions, less carcinoma will be missed and more patients will be
correctly referred to the gynaecologist (Eijsink et al, 2012). The
recently published randomised controlled trial by Verhoef et al
(2014) showed that detection of CIN2þ with methylation triage
on self-samples directly in hrHPV-positive women was non-
inferior to cytology triage on physician-taken smears, leading to a
shorter time to CIN2þ diagnosis, although referral was higher in
the methylation triage group given the positive predictive value of
this test being lower compared with cytology.
Apart from the efficacy of the screening test, the low
participation rate is another aspect in population-based screening
programs for cervical neoplasia that could be improved (Bekkers
et al, 2006). About 35% of the women in the Netherlands do not
respond to the screening invitation (referred to as non-responders).
These women are at increased risk of developing cervical cancer, as
more than 50% of the women diagnosed with cervical cancer had
no history of participating in the population-based screening
program (Peto et al, 2004; Bos et al, 2006). Introduction of self-
sampling methods for hrHPV testing has shown an increase in
participation up to 39% of these non-responders (Snijders et al,
2013). Furthermore, the response rate of the non-responders is
significantly higher when offered a self-sampling device compared
with a recall for regular cytology-based screening (Bais et al, 2007;
Gok et al, 2010; Gok et al, 2012; Racey et al, 2013).
Recent studies have shown a high concordance of hrHPV test
results between most self-collected samples and physician-taken
cervical scrapings. Even more, vaginal self-samples and physician-
taken samples showed similar test accuracy in detecting CIN2þ
lesions, especially when PCR-based HPV tests were used
(Schmeink et al, 2011; Gok et al, 2012; Snijders et al, 2013;
Arbyn et al, 2014). However, it is critical that follow-up and further
management are acceptable to the participants, especially when
participants are reluctant (Bosgraaf et al, 2013b). Therefore, direct
triage testing on self-sampled material is preferred over an extra
visit to a physician, but the concordance between cytology on self-
obtained specimens vs physician-taken samples is poor
(Nobbenhuis et al, 2002; Garcia et al, 2003; Brink et al, 2006;
Snijders et al, 2013). DNA methylation analysis directly performed
on self-sampled material might solve this problem (Eijsink et al,
2011; Hesselink et al, 2014; Verhoef et al, 2014).
The aim of the present study was (1) to compare the
performance of DNA methylation analysis with cytology as triage
test on physician-taken samples of women who previously tested
hrHPV-positive on a self-sampled specimen; (2) to analyse the
feasibility of direct triage testing with DNA methylation analysis on
brush-based self-sampled specimens and compare these results
with DNA methylation results in the matched physician-taken
samples.
MATERIALS AND METHODS
Study population. Women with a hrHPV-positive brush-based
self-sampling result (Evalyn Brush, Rovers Medical devices B.V.,
Oss, The Netherlands) were selected for this pilot study. These
women had participated in the PROHTECT-3B (PRotection by
Offering HPV TEsting on Cervico-vaginal specimens Trial-3B)
among non-responders of the Dutch screening program in the year
2008. The PROHTECT-3B study is a randomised controlled trial
designed to determine whether the participation rate for a brush-
based cervico-vaginal self-sampling device is non-inferior to the
participation rate for a lavage-based self-sampling device (Bosgraaf
et al, 2014). The study was ethically approved by the Ministry of
Health (No 2010/WBO04). In short, a total of 35 477 non-
responders of the regular cervical screening programme aged 33–
63 years were invited to participate. The self-sampling kit was sent
to the home address of all eligible women. In total, 10 027 women
participated by returning self-sampled material to the laboratory
for hrHPV testing (GP5þ /6þ PCR; EIA HPV GP HR kit;
Diassay, Voorburg, The Netherlands). All women who tested
hrHPV-negative were advised to participate in the next screening
round. All hrHPV-positive women (8.3%) were advised to comply
with an additional cervical smear taken for cytology. All
participating women gave informed consent.
Primary hrHPV testing of self-samplers. Upon arrival the dry
self-sampled brushes were resuspended in 1.5ml of ThinPrep
preservation medium (Hologic Inc., Marlborough, MA, USA). The
vials were mixed for 3 15 s, stored overnight at 4 1C and again
mixed for 2 15 s. For the primary hrHPV test, 1/10th of the self-
sampled material was used. DNA was isolated with the Roche
MagNA Pure MP 96 isolation station (Roche Diagnostics,
Indianapolis, IN, USA) and hrHPV GP5þ /6þ -PCR testing was
performed using the Diassay EIA HPV GP HR kit (Diassay),
according to the instructions of the manufacturer (van den Brule
et al, 2002).
Cytology triage testing. HrHPV-positive women underwent an
additional cervical smear taken by a physician approximately 6
weeks later. These cervical smears were collected in 20ml Thinprep
Preservcyt medium (Hologic Inc.) and cytomorphologically
assessed according to the Dutch CISOE-A classification system,
which can easily be translated into the Bethesda nomenclature
(Bulk et al, 2004). Women with abnormal cytology results
(threshold ASCUS) were referred to the gynaecologist where a
biopsy specimen was taken; if the biopsy was abnormal (CIN2þ )
they were treated according to the national guidelines in the
Netherlands (Hanselaar, 2002). Women with normal cytology were
re-invited after 6 months for a repeat cervical scraping for cytology
and hrHPV co-testing. If one of these tests was abnormal, women
were referred for colposcopy-directed biopsy; if there was a double-
negative test result, they were advised to attend the next regular
screening round.
Sample selection for the current DNA methylation study. The
triage physician-taken samples of PROHTECT-3B study were used
to compare the performance of DNA methylation analysis vs
cytology as a triage test. Histology results were set as the gold
standard. For this pilot study, a total of 128 women were selected
based on different subgroups (Figure 1): women who were true-
positive by cytology (abnormal cytology and abnormal histology,
i.e., CIN2þ ); false-positive by cytology (abnormal cytology and
normal histology, i.e., no CIN/CIN1); true-negative by cytology
(twice normal cytology; at baseline and after 6 months) and false-
negative by cytology (baseline normal cytology and at 6 months
abnormal histology, i.e., CIN2þ ).
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To analyse the feasibility of direct triage testing with DNA
methylation analysis on brush-based self-sampled material, a small
group of 50 hrHPV-positive women were analysed for this study.
These 50 hrHPV-positive women had subsequently undergone an
additional cervical smear by a physician B6 weeks later. About
half of the group (n¼ 24) had an abnormal histological outcome
(CIN3þ ), and half of the group (n¼ 26) had a normal histological
outcome (pCIN2).
DNA extraction, bisulfite treatment and QMSP. For quantitative
methylation-specific PCR, a new DNA isolation was performed
using 5ml of the 20ml physician-taken specimen and the
remaining material (9/10th) of the self-sampled specimen.
Genomic DNA was isolated by standard overnight proteinase K
treatment, salt-chloroform extraction, and isopropanol precipita-
tion (Eijsink et al, 2012) DNA quality was assessed according to the
BIOMED-2 protocol (van Dongen et al, 2003). Sodium bisulfite
treatment on isolated genomic DNA (1 mg per sample) was
performed according to the manufacturer’s protocol of the EZ
DNA methylation kit (Zymo Research Corp, Irvine, CA, USA).
Quantitative methylation-specific PCR was performed with
bisulfite-treated DNA using an internal (FAM/TAMRA)-labelled
hybridisation probe for quantitative analyses of four genes
(C13ORF18, JAM3, EPB41L3 and TERT). Quantitative methyla-
tion-specific PCR conditions and primer and probe sequences are
as described previously (Eijsink et al, 2011; Eijsink et al, 2012). To
correct for DNA input, QMSP of the housekeeping gene
b-actin was used. Quantitative methylation-specific PCR reactions
were performed in a total volume of 20 ml, containing 10 ml of 2
QuantiTect Probe Mastermix (Qiagen, Hilden, Germany), 600 nM
of forward and reverse primers (Invitrogen, Carlsbad, CA, USA),
250 nM of hybridisation probe (IDT, Leuven, Belgium) and 50 ng
bisulphite-modified DNA. Each sample was analysed in triplicate
in a 384-well plate using ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems, Life Technologies, Carlsbad, CA,
USA). A pool of leukocyte DNA from healthy women was used as
a negative control. As a positive control, in vitro methylated (by
SssI enzyme) leukocyte DNA was used in each experiment. All
amplification curves were visualised and scored without knowledge
of clinical data. A DNA sample was considered methylated if at
least 2 out of the 3 wells were methylation positive with a Ct-value
below 50 and DNA input of at least 225 pg b-actin. Quantitative
methylation-specific PCR values were adjusted for DNA input by
expressing results as ratios between two absolute measurements
((average DNA quantity of methylated gene of interest/average
DNA quantity for reference gene b-actin) 10 000) (Wisman et al,
2006).
Statistical analysis. Statistical analysis was performed using SPSS
software package (SPSS 20, Chicago, IL, USA). Histology was set as
the gold standard. Methylation levels per gene were compared with
the severity of the underlying lesion by the Kruskall–Wallis
test. Sensitivity and specificity were calculated with CIN2þ and
CIN3þ as cutoff. Methylation levels per gene with CIN3þ as
cutoff were visualised in a receiver-operating characteristic (ROC)
curve. To compare sensitivity and specificity of triage testing by
DNA methylation vs triage testing by cytology on the same group
of patients, the extended McNemar test, described by Hawass
(1997) was executed. Concordance between the DNA methylation
analysis of the Evalyn Brush self-samples and paired physician-
taken liquid-based samples was measured by Cohen’s Kappa.
Correlation of DNA methylation ratio in the paired physician-
taken liquid-based samples and Evalyn Brush self-samples was
measured by the Spearman rank analysis; differences with a P-
value o0.05 were considered statistically significant.
RESULTS
Performance of DNA methylation analysis in physician-taken
samples. Liquid-based physician-taken samples of 128 hrHPV-
positive women were used for QMSP of C13ORF18, JAM3,
EPB41L3 and TERT. Methylation levels increased with the severity
of the underlying lesion for all genes (Po0.001) (data not shown).
Table 1 shows the methylation positivity per subgroup. The patient
group with abnormal cytology and CIN3þ lesions was methyla-
tion positive for C13ORF18 and JAM3 in 65% (20/31) and 84%
(26/31) of the cases, respectively, whereas the group with abnormal
cytology and normal histology showed DNA methylation positivity
in only 8% (4/49) and 16% (8/49) of these cases, respectively.
Table 2 shows the accuracy of DNA methylation analysis and
cytology for detection of CIN2þ and CIN3þ . DNA methylation
analysis of JAM3 showed the highest combined sensitivity (82%)
and specificity (88%) for detection of CIN3þ , whereas cytology
showed a specificity of 48% and a sensitivity of 91%. Sensitivities
for CIN3þ of JAM3 (82%), EPB41L3 (88%) and TERT (76%) were
comparable to cytology (91%), whereas specificities for JAM3
(88%) and C13ORF18 (91%) were significantly better than for
cytology (48%) (Po0.001). For each marker, ROC curves for
CIN3þ were computed (Figure 2). The areas under the curve were
0.855 for JAM3, 0.881 for EPB41L3 and 0.795 for C13ORF18 and
TERT.
DNA methylation analysis on self-sampled material and its
correlation with physician-taken material. From 50 patients with
a liquid-based physician-taken sample also the matched original
Evalyn Brush self-samples were used to perform the DNA
methylation analysis. High-quality DNA could be retrieved from
49 brush devices. Performance of DNA methylation analysis
directly on original self-sampled material showed again high
hrHPV-positive with a brush-
based self-sampling device
Cytology triage with a
physician-taken sample (n =128) 
Normal cytology (n =48) Abnormal cytology (n =80) 
Abnormal repeat cytology
Histology : CIN2+ 
False negative 
by cytology (n =8)
Normal repeat cytology
True negative
by cytology (n =40)
Histology: no CIN/CIN1
False positive 
by cytology (n=39) 
Histology: CIN2+
True positive 
by cytology (n=41) 
Figure 1. Study design.
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specificities for JAM3 and C13ORF18 (both 96%), with corre-
sponding sensitivities of 71% and 54% for CIN3þ , respectively,
(Table 3). Also EPB41L3 showed high specificity (88%) with
corresponding high sensitivity (79%). The agreement between the
methylation outcome of the Evalyn Brush self-sampled specimen
and the liquid-based samples taken by the physician was 90% for
C13ORF18 (k¼ 0.77, Po0.001), 88% for JAM3 (k¼ 0.75,
Po0.001), 80% for EPB41L3 (k¼ 0.59, Po0.001) and 71% for
TERT (k¼ 0.41, P¼ 0.003). Comparing the methylation ratios
between the matched self- and physician-taken samples showed
again a very high concordance (Po0.001), with the best results for
C13ORF18 (r¼ 0.82, Po0.001), EPB41L3 (r¼ 0.84, Po0.001) and
JAM3 (r¼ 0.89, Po0.001) methylation (Figure 3).
DISCUSSION
This study shows for the first time that DNA methylation analysis
is feasible on brush-based self-sampled cervico-vaginal material.
The concordance between DNA methylation analysis on self-
sampled material and physician-taken samples in this study was
high. Furthermore, the clinical performance of DNA methylation
analysis as triage test on both hrHPV-positive physician-taken
samples and self-collected samples was good, with high specificity,
Table 2. Sensitivity and specificity of methylation markers and cytology on physician-taken material for CIN2þ and CIN3þ (n¼ 128)
Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI)
Test CIN2þ CIN3þ
C13ORF18 49% (34.4–63.7) 92% (84.2–97.1) 65% (46.5–80.2) 91% (83.9–96.2)
JAM3 63% (48.3–76.6) 90% (81.0–95.5) 82% (65.5–93.2) 88% (80.0–94.0)
EPB41L3 67% (52.5–80.0) 57% (45.3–68.1) 88% (72.5–96.6) 61% (50.0–70.6)
TERT 69% (54.6–81.7) 62% (50.4–72.7) 76% (58.8–89.2) 60% (49.0–69.6)
Abnormal cytology (XASCUS) 84% (70.3–92.7) 51% (39.1–62.1) 91% (76.3–98.0) 48% (37.5–58.4)
Abbreviations: ASCUS¼ atypical squamous cells of undetermined significance; CI¼ confidence interval.





Abnormal cytology at baseline
(XASCUS)
Normal cytology (NILM)
at baseline and follow-up No CIN CIN1 CIN2 CIN3 CIN2 CIN3 Cancer
C13ORF18 2/40 (5%) 1/18 (6%) 3/21 (14%) 2/5 (40%) 2/3 (67%) 0/10 (0%) 13/22 (59%) 7/9 (78%)
JAM3 3/40 (8%) 2/18 (11%) 3/21 (14%) 0/5 (0%) 2/3 (67%) 3/10 (30%) 17/22 (77%) 9/9 (100%)
EPB41L3 10/40 (25%) 10/18 (56%) 14/21 (67%) 0/5 (0%) 2/3 (67%) 3/10 (30%) 19/22 (86%) 9/9 (100%)
TERT 13/40 (33%) 9/18 (50%) 8/21 (38%) 4/5 (80%) 2/3 (67%) 4/10 (40%) 15/22 (68%) 9/9 (100%)























Cytology: ASCUS or worse
Figure 2. ROC curves for methylation ratio of C13ORF18, JAM3,
EPB41L3 and TERT for CIN3þ .
Table 3. Sensitivity and specificity of methylation markers on brush-based
self-sampled material for CIN3þ (n¼49)
Test Sensitivity (95% CI) Specificity (95% CI)
C13ORF18 54% (35–72%) 96% (80–99%)
JAM3 71% (51–85%) 96% (80–99%)
EPB41L3 79% (60–91%) 88% (70–96%)
TERT 54% (35–72%) 80% (61–91%)
Abbreviation: CI¼ confidence interval.
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particularly for C13ORF18 and JAM3, and moderate to high
sensitivity in the studied series.
The sensitivity of hrHPV assays evaluated in primary
screening appeared consistently high for detection of CIN3þ
(Arbyn et al, 2012). In primary screening this higher clinical
sensitivity may lead to earlier diagnosis of high-grade cervical
lesions and prevent cervical cancer (Ronco et al, 2013). However,
hrHPV screening is less specific, especially for young women,
resulting in a relatively high false-positive rate (Cuzick et al, 2006).
With a triage test, specificity can be improved and this results in
fewer referrals for colposcopy, reduction of overtreatment and
anxiety of false-positive women and also reduces the costs
(Bosgraaf et al, 2013a). Cytology as triage test, as suggested in
the new Dutch HPV-screening program, will ensure that most
women with underlying CIN2þ lesions are correctly referred for
colposcopy (Ministry of Health, Welfare and Sport, 2013).
However, in this study we showed that specificity could be further
improved by the use of DNA methylation.
The high-sensitivity and low-specificity results of cytology
found in this study might be explained by the cytologist’s
awareness of the HPV-positive results. Furthermore, the sample
selection was based on different subgroups, and is therefore not
representative for the whole group. Nonetheless, in these specified
selected subgroups, our findings point to the methylation test as an
attractive alternative to cytology as a triage test. The advantage of
DNA methylation analysis as a triage test on cervical smear in
comparison with cytology is that it is an objective, non-
morphological test. In this study, we showed a high specificity of
C13ORF18 and JAM3 methylation for CIN3þ , and a moderate to
high sensitivity for C13ORF18, JAM3 and EPB41L3. In addition, we
showed in the group ‘false-positive by cytology’ (abnormal cytology
and normal histology) that methylation positivity was very low,
which in a screening context would result in a reduction of
referrals of false-positive women to the gynaecologist. In addition,
the methylation test detected out of 3 women with a CIN3 lesion
who were missed with cytology triage testing.
DNA methylation analysis in self-sampled cervico-vaginal brush
specimens showed high specificity and moderate to high sensitivity
for detection of CIN3þ lesions. The concordance between
DNA methylation analysis on the self-sampled material and the
corresponding physician-taken sample takenB6 weeks later from
the same patient was high, which supports reliability of the
methylation test in the self-sampled material. An advantage of
DNA methylation analysis performed directly on self-sampled
material is that it eliminates the need for an additional cervical
smear. As a result, loss to follow-up could decrease, especially in
the non-responder group. Large population-based studies in non-
responders of the regular cervical cancer screening showed that
about 10% of the HPV-positive women did not visit their physician
for triage cytology (Gok et al, 2010; Gok et al, 2012).
Previously, we evaluated the same four genes (C13ORF18,
JAM3, EPB41L3 and TERT) by DNA methylation analysis on self-
sampled material obtained by a lavage device (Eijsink et al, 2011).
In the current study, we showed representative methylation results
for these four genes, and we also showed that DNA methylation
analysis on self-samples by a dry cervical brush device can be used
as well. The use of dry brush devices may have advantages over
cervico-vaginal lavage devices, as brushes can be transported and
stored dry, whereas liquid specimens are less convenient for
sending by regular mail (van Baars et al, 2012). But above all, both
devices are not suitable for cytological examination (Snijders et al,
2013). Therefore, DNA methylation is more suitable for triage
testing after hrHPV self-sampling compared with cytology. In the
current study, we analysed four genes, previously validated (Eijsink
et al, 2011; Eijsink et al, 2012), of which some showed already
better specificity compared with cytology without losing sensitivity
to detect CIN3þ . The advantage of using these particular genes is
that setting a cutoff value is not needed. If the PCR product was
negative (i.e., no amplification of specific product), the sample was
called negative and any ratio above zero for two PCR products
(analysed in triplicate) was called positive. This unique feature of
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Figure 3. Methylation ratio of C13ORF18, JAM3, EPB41L3 and TERT as determined in self-sampled material and in matched physician-taken
triage material.
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Furthermore, also other groups describe some of these genes (e.g.,
EPB41L3) as predictors for CIN2/3 lesions (Brentnall et al, 2014;
Vasiljevic et al, 2014). Addition of other potential markers reported
(Wentzensen et al, 2009; Lai et al, 2010; Overmeer et al, 2011;
Lendvai et al, 2012; Bierkens et al, 2013; Verhoef et al, 2014) or
identification of even better differentially methylated genes by
genome-wide methods could even further improve the diagnostic
accuracy of DNA methylation in the future.
Although the present study included a relatively small number
of samples and comprised a selected series, it had several strengths.
The primary HPV tests as well as DNA methylation analysis were
both performed on the same self-sampled material. In addition, the
matched physician-taken liquid-based cytology samples were
available for DNA methylation analysis and this allowed direct
comparison between DNA methylation analyses on self-samplers
vs physician-taken samples. A limitation of our study is the lack of
histology; the medical ethics committee did not allow to take
cervical biopsies in women with normal triage cytology and normal
follow-up cytology after 6 months, which may lead to an under- or
overestimation of the exact performance of DNA methylation in
the triage of these screening results.
In conclusion, DNA methylation analysis is feasible on
brush-based self-sampled material, and its diagnostic perfor-
mance as triage test for hrHPV-positive women showed
similar results as DNA methylation analysis on physician-taken
samples. Direct methylation analysis on self-sampled material
could be an important step forward in optimising the screening
programme, as this would eliminate the need for an extra
physician-taken cervical scraping for triage testing. In addition,
owing to its high specificity it would reduce the number of false-
positive women referred to the gynaecologist. Our data indicate
that the detection of cervical neoplasia by DNA methylation
analysis in cervico-vaginal brush specimens warrants further
exploration of its use in large population-based prospective
cohort studies.
REFERENCES
Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G,
Naucler P, Sankaranarayanan R, Peto J (2012) Evidence regarding human
papillomavirus testing in secondary prevention of cervical cancer. Vaccine
30(Suppl 5): F88–F99.
Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L,
Minozzi S, Bellisario C, Banzi R, Zhao FH, Hillemanns P, Anttila A (2014)
Accuracy of human papillomavirus testing on self-collected versus
clinician-collected samples: a meta-analysis. Lancet Oncol 15: 172–183.
Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F,
Babovic M, van Ballegooijen M, Helmerhorst TJ, Meijer CJ (2007) Human
papillomavirus testing on self-sampled cervicovaginal brushes: an effective
alternative to protect nonresponders in cervical screening programs.
Int J Cancer 120: 1505–1510.
Bekkers RL, Meijer CJ, Massuger LF, Snijders PJ, Melchers WJ (2006) Effects
of HPV detection in population-based screening programmes for cervical
cancer; a Dutch moment. Gynecol Oncol 100: 451–454.
Bierkens M, Hesselink AT, Meijer CJ, Heideman DA, Wisman GB,
van der Zee AG, Snijders PJ, Steenbergen RD (2013) CADM1 and MAL
promoter methylation levels in hrHPV-positive cervical scrapes increase
proportional to degree and duration of underlying cervical disease. Int J
Cancer 133: 1293–1299.
Bos AB, Rebolj M, Habbema JD, van Ballegooijen M (2006) Nonattendance is
still the main limitation for the effectiveness of screening for cervical
cancer in the Netherlands. Int J Cancer 119: 2372–2375.
Bosgraaf RP, Mast PP, Struik-van der Zanden PH, Bulten J, Massuger LF,
Bekkers RL (2013a) Overtreatment in a see-and-treat approach to cervical
intraepithelial lesions. Obstet Gynecol 121: 1209–1216.
Bosgraaf RP, Siebers AG, De Hullu JA, Massuger LF, Bulten J, Bekkers RL,
Melchers WJ (2013b) The current position and the future perspectives of
cervical cancer screening. Expert Rev Anticancer Ther 14: 75–92.
Bosgraaf RP, Verhoef VM, Massuger LF, Siebers AG, Bulten J,
de Kuyper-de Ridder GM, Meijer CJ, Snijders PJ, Heideman DA,
IntHout J, van Kemenade FJ, Melchers WJ, Bekkers RL (2014)
Comparative performance of novel self-sampling methods in detecting
high-risk human papillomavirus in 30 130 women not attending cervical
screening. Int J Cancer; e-pub ahead of print 13 June 2014; doi:10.1002/
ijc.29026.
Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J,
Szarewski A, Cuzick J, Lorincz AT (2014) A DNA methylation classifier of
cervical precancer based on human papillomavirus and human genes.
Int J Cancer; e-pub ahead of print 18 February 2014; doi:10.1002/ijc.28790.
Brink AA, Meijer CJ, Wiegerinck MA, Nieboer TE, Kruitwagen RF,
van Kemenade F, Fransen Daalmeijer N, Hesselink AT, Berkhof J,
Snijders PJ (2006) High concordance of results of testing for human
papillomavirus in cervicovaginal samples collected by two methods, with
comparison of a novel self-sampling device to a conventional endocervical
brush. J Clin Microbiol 44: 2518–2523.
Bulk S, Van Kemenade FJ, Rozendaal L, Meijer CJ (2004) The Dutch CISOE-
A framework for cytology reporting increases efficacy of screening upon
standardisation since 1996. J Clin Pathol 57: 388–393.
Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A,
Birembaut P, Kulasingam S, Sasieni P, Iftner T (2006) Overview of the
European and North American studies on HPV testing in primary cervical
cancer screening. Int J Cancer 119: 1095–1101.
Dijkstra MG, van Niekerk D, Rijkaart DC, van Kemenade FJ, Heideman DA,
Snijders PJ, Meijer CJ, Berkhof J (2014) Primary hrHPV DNA testing in
cervical cancer screening: how to manage screen-positive women? A
POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev 23: 55–63.
Eijsink JJ, Lendvai A, Deregowski V, Klip HG, Verpooten G, Dehaspe L,
de Bock GH, Hollema H, van Criekinge W, Schuuring E, van der Zee AG,
Wisman GB (2012) A four-gene methylation marker panel as triage test in
high-risk human papillomavirus positive patients. Int J Cancer 130:
1861–1869.
Eijsink JJ, Yang N, Lendvai A, Klip HG, Volders HH, Buikema HJ,
van Hemel BM, Voll M, Coelingh Bennink HJ, Schuuring E, Wisman GB,
van der Zee AG (2011) Detection of cervical neoplasia by DNA
methylation analysis in cervico-vaginal lavages, a feasibility study. Gynecol
Oncol 120: 280–283.
Garcia F, Barker B, Santos C, Brown EM, Nuno T, Giuliano A, Davis J (2003)
Cross-sectional study of patient- and physician-collected cervical cytology
and human papillomavirus. Obstet Gynecol 102: 266–272.
Gok M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW,
Voorhorst F, Belien JA, Babovic M, Snijders PJ, Meijer CJ (2010) HPV
testing on self collected cervicovaginal lavage specimens as screening
method for women who do not attend cervical screening: cohort study.
BMJ 340: c1040.
Gok M, van Kemenade FJ, Heideman DA, Berkhof J, Rozendaal L, Spruyt JW,
Belien JA, Babovic M, Snijders PJ, Meijer CJ (2012) Experience with
high-risk human papillomavirus testing on vaginal brush-based self-
samples of non-attendees of the cervical screening program. Int J Cancer
130: 1128–1135.
Hanselaar AG (2002) Criteria for organized cervical screening programs.
Special emphasis on The Netherlands program. Acta Cytol 46: 619–629.
Hawass NE (1997) Comparing the sensitivities and specificities of two
diagnostic procedures performed on the same group of patients.
Br J Radiol 70: 360–366.
Hesselink AT, Heideman DA, Steenbergen RD, Coupe VM, Overmeer RM,
Rijkaart D, Berkhof J, Meijer CJ, Snijders PJ (2011) Combined promoter
methylation analysis of CADM1 and MAL: an objective triage tool for
high-risk human papillomavirus DNA-positive women. Clin Cancer Res
17: 2459–2465.
Hesselink AT, Heideman DA, Steenbergen RD, Gok M, van Kemenade FJ,
Wilting SM, Berkhof J, Meijer CJ, Snijders PJ (2014) Methylation marker
analysis of self-sampled cervico-vaginal lavage specimens to triage high-
risk HPV-positive women for colposcopy. Int J Cancer 135: 880–886.
Lai HC, Lin YW, Huang RL, Chung MT, Wang HC, Liao YP, Su PH, Liu YL,
Yu MH (2010) Quantitative DNA methylation analysis detects cervical
intraepithelial neoplasms type 3 and worse. Cancer 116: 4266–4274.
Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, Liu J, Chan MW,
Chu TY, Sun CA, Chang CC, Yu MH (2008) Identification of novel DNA
methylation markers in cervical cancer. Int J Cancer 123: 161–167.
Lendvai A, Johannes F, Grimm C, Eijsink JJ, Wardenaar R, Volders HH,
Klip HG, Hollema H, Jansen RC, Schuuring E, Wisman GB,
BRITISH JOURNAL OF CANCER DNA methylation analysis in hrHPV-positive women
1100 www.bjcancer.com |DOI:10.1038/bjc.2014.392
van der Zee AG (2012) Genome-wide methylation profiling identifies
hypermethylated biomarkers in high-grade cervical intraepithelial
neoplasia. Epigenetics 7: 1268–1278.
Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J,
Ferenczy A, Ratnam S, Coutlee F, Franco EL. Canadian Cervical Cancer
Screening Trial Study Group (2007) Human papillomavirus DNA versus
Papanicolaou screening tests for cervical cancer. N Engl J Med 357:
1579–1588.
Ministry of Health, Welfare and Sport (2013) [Letter to the House of
Representatives of the Dutch parliament: Improvement of the Dutch
cervical cancer screening].
Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Jaspars LH,
Voorhorst FJ, Verheijen RH, Meijer CJ (2002) Primary screening for high
risk HPV by home obtained cervicovaginal lavage is an alternative
screening tool for unscreened women. J Clin Pathol 55: 435–439.
Overmeer RM, Henken FE, Bierkens M, Wilting SM, Timmerman I,
Meijer CJ, Snijders PJ, Steenbergen RD (2009) Repression of MAL
tumour suppressor activity by promoter methylation during cervical
carcinogenesis. J Pathol 219: 327–336.
Overmeer RM, Louwers JA, Meijer CJ, Van Kemenade FJ, Hesselink AT,
Daalmeijer NF, Wilting SM, Heideman DA, Verheijen RH, Zaal A,
Marchien VB, Berkhof J, Snijders PJ, Steenbergen RD (2011)
Combined CADM1 and MAL promoter methylation analysis to detect
(pre-)malignant cervical lesions in high-risk HPV-positive women.
Int J Cancer 129: 2218–2225.
Peto J, Gilham C, Fletcher O, Matthews FE (2004) The cervical cancer
epidemic that screening has prevented in the UK. Lancet 364: 249–256.
Racey CS, Withrow DR, Gesink D (2013) Self-collected HPV testing improves
participation in cervical cancer screening: a systematic review and
meta-analysis. Can J Public Health 104: e159–e166.
Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW,
Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ (2012a)
Human papillomavirus testing for the detection of high-grade cervical
intraepithelial neoplasia and cancer: final results of the POBASCAM
randomised controlled trial. Lancet Oncol 13: 78–88.
Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT,
Rozendaal L, Heideman DA, Verheijen RH, Bulk S, Verweij WM,
Snijders PJ, Meijer CJ (2012b) Evaluation of 14 triage strategies for HPV
DNA-positive women in population-based cervical screening. Int J Cancer
130: 602–610.
Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M,
Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J,
Meijer CJ. the International HPV screening working group (2013) Efficacy
of HPV-based screening for prevention of invasive cervical cancer:
follow-up of four European randomised controlled trials. Lancet 383:
524–532.
Schmeink CE, Bekkers RL, Massuger LF, Melchers WJ (2011) The potential
role of self-sampling for high-risk human papillomavirus detection in
cervical cancer screening. Rev Med Virol 21: 139–153.
Snijders PJ, Verhoef VM, Arbyn M, Ogilvie G, Minozzi S, Banzi R,
van Kemenade FJ, Heideman DA, Meijer CJ (2013) High-risk HPV testing
on self-sampled versus clinician-collected specimens: a review on the
clinical accuracy and impact on population attendance in cervical cancer
screening. Int J Cancer 132: 2223–2236.
van Baars R, Bosgraaf RP, ter Harmsel BW, Melchers WJ, Quint WG,
Bekkers RL (2012) Dry storage and transport of a cervicovaginal
self-sample by use of the Evalyn Brush, providing reliable human
papillomavirus detection combined with comfort for women. J Clin
Microbiol 50: 3937–3943.
van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ,
Snijders PJ (2002) GP5þ /6þ PCR followed by reverse line blot analysis
enables rapid and high-throughput identification of human
papillomavirus genotypes. J Clin Microbiol 40: 779–787.
van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M,
Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R,
van Krieken JH, Droese J, Gonzalez D, Bastard C, White HE,
Spaargaren M, Gonzalez M, Parreira A, Smith JL, Morgan GJ, Kneba M,
Macintyre EA (2003) Design and standardization of PCR primers and
protocols for detection of clonal immunoglobulin and T-cell receptor gene
recombinations in suspect lymphoproliferations: report of the BIOMED-2
Concerted Action BMH4-CT98-3936. Leukemia 17: 2257–2317.
Vasiljevic N, Scibior-Bentkowska D, Brentnall AR, Cuzick J, Lorincz AT
(2014) Credentialing of DNA methylation assays for human genes as
diagnostic biomarkers of cervical intraepithelial neoplasia in high-risk
HPV positive women. Gynecol Oncol 132: 709–714.
Verhoef VM, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DA,
Hesselink AT, Bekkers RL, Steenbergen RD, Massuger LF, Melchers WJ,
Bulten J, Overbeek LI, Berkhof J, Snijders PJ, Meijer CJ (2014) Triage by
methylation-marker testing versus cytology in women who test
HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3):
a randomised controlled non-inferiority trial. Lancet Oncol 15:
315–322.
Wentzensen N, Sherman ME, Schiffman M, Wang SS (2009) Utility of
methylation markers in cervical cancer early detection: appraisal of the
state-of-the-science. Gynecol Oncol 112: 293–299.
Wisman GB, Nijhuis ER, Hoque MO, Reesink-Peters N, Koning AJ,
Volders HH, Buikema HJ, Boezen HM, Hollema H, Schuuring E,
Sidransky D, van der Zee AG (2006) Assessment of gene promoter
hypermethylation for detection of cervical neoplasia. Int J Cancer 119:
1908–1914.
Woodman CB, Collins SI, Young LS (2007) The natural history of cervical
HPV infection: unresolved issues. Nat Rev Cancer 7: 11–22.
Yang N, Nijhuis ER, Volders HH, Eijsink JJ, Lendvai A, Zhang B, Hollema H,
Schuuring E, Wisman GB, van der Zee AG (2010) Gene promoter
methylation patterns throughout the process of cervical carcinogenesis.
Cell Oncol 32: 131–143.
Zorzi M, Del Mistro A, Farruggio A, de’Bartolomeis L, Frayle-Salamanca H,
Baboci L, Bertazzo A, Cocco P, Fedato C, Gennaro M, Marchi N,
Penon MG, Cogo C, Ferro A (2013) Use of a high-risk human
papillomavirus DNA test as the primary test in a cervical cancer screening
programme: a population-based cohort study. BJOG 120: 1260–1267.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 3.0 Unported License.
DNA methylation analysis in hrHPV-positive women BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.392 1101
